Watanabe T, Brown G S, Kelsey L S, Yan Y, Jackson J D, Ewel C, Kessinger A, Talmadge J E
Department of Pathology, University of Nebraska Medical Center, Omaha 68198-5660, USA.
Exp Hematol. 1996 May;24(6):713-21.
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) demonstrated hemato-protective activity in mice after sublethal irradiation (7 GY). Bone marrow interleukin-3 (IL-3)-responsive colony-forming cells (CFC and high proliferative potential colony-forming cells (HPP-CFC) were significantly (p < 0.05) increased by day 10 after irradiation in mice receiving a continuous infusion of 1000 ng/day of AcSDKP compared to irradiated control mice. The maximum protective effect for bone marrow progenitors was achieved when AcSDKP was administered for 3 days beginning 24 hours before irradiation. Other dosages and schedules in relationship to irradiation were less active. Further, when granulocyte colony-stimulating factor (G-CSF) was administered for 10 days beginning 24 hours before irradiation. Other dosages and schedules in relationship to irradiation were less active. Further, when granulocyte colony-stimulating factor (G-CSF) was administered for 10 days after AcSDKP infusion in irradiated mice, significantly increased numbers of IL-3 responsive CSF-only control mice. In addition, platelets were significantly (p < 0.05) increased in mice receiving AcSDKP and G-CSF on days 18 and 21 after irradiation compared with mice receiving G-CSF alone. We conclude that ACSDKP has a radioprotective effect in vivo for progenitor cells, and that time of initiation and duration of AcSDKP administration relative to irradiation are crucial for these effects. Further, AcSDKP has a significant additive protective effect not only for progenitor cells but also for platelets when given in combination with G-CSF. We suggest that these in vivo observations provide a basis on which to design optimal clinical hypothesis and protocols.
乙酰 - N - 丝氨酸 - 天冬氨酸 - 赖氨酸 - 脯氨酸(AcSDKP)在亚致死剂量照射(7戈瑞)后的小鼠中表现出血液保护活性。与接受照射的对照小鼠相比,在连续输注1000纳克/天AcSDKP的小鼠中,照射后第10天骨髓白细胞介素 - 3(IL - 3)反应性集落形成细胞(CFC)和高增殖潜能集落形成细胞(HPP - CFC)显著(p < 0.05)增加。当在照射前24小时开始给予AcSDKP 3天时,对骨髓祖细胞可达到最大保护作用。与照射相关的其他剂量和给药方案活性较低。此外,当在照射前24小时开始给予粒细胞集落刺激因子(G - CSF)10天时,与仅给予G - CSF的对照小鼠相比,照射小鼠在输注AcSDKP后给予G - CSF,IL - 3反应性细胞数量显著增加。另外,与仅接受G - CSF的小鼠相比,照射后第18天和第21天接受AcSDKP和G - CSF的小鼠血小板显著(p < 0.05)增加。我们得出结论,ACSDKP对体内祖细胞具有辐射保护作用,并且相对于照射,AcSDKP给药的起始时间和持续时间对这些作用至关重要。此外,当与G - CSF联合使用时,AcSDKP不仅对祖细胞而且对血小板具有显著的附加保护作用。我们认为这些体内观察结果为设计最佳临床假设和方案提供了基础。